Isolation and Characterization of NP-POL Nonapeptide for Possible Therapeutic Use in Parkinson’s Disease

Figure 4

The neuroprotective effect of the NP-POL peptide on NGF-differentiated PC12 cell viability treated with 6-OHDA neurotoxin. (a) Control, (b) NP-POL 1 μg/ml, (c) NP-POL 10 μg/ml, (d) NP-POL 100 μg/ml, (e) 6-OHDA 160 μM, (f) NP-POL 1 μg/ml + 6-OHDA 160 μM, (g) NP-POL 10 μg/ml + 6-OHDA 160 μM, and (h) NP-POL 100 μg/ml + 6-OHDA 160 μM. Scale bar = 50 μM.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)